Related Experiment Video

Updated: Apr 11, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.7K

Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors

A J Scott1, W A Messersmith1, A Jimeno2

  • 1Division of Hematology and Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.

Drugs of Today (Barcelona, Spain : 1998)
|May 29, 2015
PubMed

Insights

Apatinib, a VEGFR-2 inhibitor, shows promise in treating various solid tumors by targeting proangiogenic pathways. This oral medication offers a survival benefit and a favorable side effect profile, expanding cancer treatment options.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant proangiogenic pathways are key drivers of tumor growth and metastasis.
  • Antiangiogenic therapies targeting these pathways have demonstrated clinical efficacy in diverse solid tumors.
  • Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) is a critical mediator of angiogenesis.

Purpose of the Study:

  • To evaluate the therapeutic potential of apatinib, a small-molecule VEGFR-2 inhibitor.
  • To assess the efficacy and safety of apatinib in various solid tumor types.
  • To determine if apatinib can improve outcomes in patients with advanced cancers.

Main Methods:

  • Apatinib, an orally bioavailable small-molecule inhibitor, was investigated.
  • Clinical trials were conducted across multiple tumor types, including gastric and non-small cell lung cancer.
  • Efficacy, survival benefit, and side effect profiles were assessed.

Main Results:

  • Apatinib demonstrated a survival benefit in gastric cancer (Phase III) and non-small cell lung cancer (Phase II).
  • The agent is orally bioavailable, offering a convenient administration route.
  • Apatinib exhibited a favorable side effect profile compared to other antiangiogenic agents.

Conclusions:

  • Apatinib represents a promising therapeutic option for a range of solid tumors.
  • Its efficacy in inhibiting VEGFR-2-mediated angiogenesis contributes to improved patient outcomes.
  • Apatinib has the potential to augment current treatment strategies in oncology.
Keywords:
Antiangiogenic drugsApatinibSolid tumorVEGFVEGFR-2

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
661
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
568
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K